Acute Migraine Medications and Evolution From Episod Longitudinal Populationâ€Based Study

Headache

48, 1157-1168

DOI: 10.1111/j.1526-4610.2008.01217.x

Citation Report

#	Article	IF	CITATIONS
1	Diagnostic issues in tension-type headache. Current Pain and Headache Reports, 2008, 12, 437-441.	1.3	5
2	Advances in the pharmacologic treatment of tension-type headache. Current Pain and Headache Reports, 2008, 12, 442-446.	1.3	17
3	Migraine: improved outcomes in patients previously poorly responsive to therapy. International Journal of Clinical Practice, 2008, 62, 1822-1824.	0.8	0
4	Excessive acute migraine medication use and migraine progression. Neurology, 2008, 71, 1821-1828.	1.5	244
5	Clinical course in migraine. Neurology, 2008, 71, 848-855.	1.5	190
7	Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arquivos De Neuro-Psiquiatria, 2009, 67, 559-569.	0.3	23
8	Zolmitriptan and the Triptan Era. Clinical Medicine Therapeutics, 2009, 1, CMT.S2907.	0.1	0
9	Adverse effects of medications commonly used in the treatment of migraine. Expert Review of Neurotherapeutics, 2009, 9, 1379-1391.	1.4	41
10	Question & amp; Answer Session. Cephalalgia, 2009, 29, 22-24.	1.8	6
11	What predicts the change from episodic to chronic migraine?. Current Opinion in Neurology, 2009, 22, 269-276.	1.8	119
12	Review of comorbidities and risk factors for the development of migraine complications (infarct and) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
13	Chronic Daily Headaches in Children and Adolescents. Seminars in Pediatric Neurology, 2009, 16, 31-33.	1.0	6
14	Headache: challenging conventional wisdom. Lancet Neurology, The, 2009, 8, 12-14.	4.9	7
15	Triptanâ€induced latent sensitization: A possible basis for medication overuse headache. Annals of Neurology, 2010, 67, 325-337.	2.8	181
16	Predictors of variability in urinary incontinence and overactive bladder symptoms. Neurourology and Urodynamics, 2010, 29, 328-335.	0.8	18
17	Practical strategies for treating chronic migraine with medication overuse: case examples and role play demonstrations. Neurological Sciences, 2009, 30, 95-99.	0.9	3
19	The epidemiology of chronic daily headache. Current Pain and Headache Reports, 2009, 13, 59-63.	1.3	20
20	Overuse of acute migraine medications and migraine chronification. Current Pain and Headache Reports, 2009, 13, 301-307.	1.3	109

#	ARTICLE	IF	CITATIONS
21	Tension-type headache with medication overuse: Pathophysiology and clinical implications. Current Pain and Headache Reports, 2009, 13, 463-469.	1.3	10
22	The effects of chronic administration of sumatriptan and dipyrone on serotonergic system in the rat brain: an immunohistochemical study. Acta Neurologica Scandinavica, 2009, 120, 264-269.	1.0	1
23	Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis. Headache, 2009, 49, 395-403.	1.8	49
24	Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2009, 49, 498-508.	1.8	255
25	Barriers to Satisfactory Migraine Outcomes. What Have We Learned, Where Do We Stand?. Headache, 2009, 49, 1028-1041.	1.8	39
27	From the Editorial Office. Headache, 2009, 49, 1126-1127.	1.8	O
28	Expanding Access to Triptans: Assessment of Clinical Outcome. Headache, 2009, 49, 1402-1413.	1.8	3
29	Assessment and Treatment of Pain Associated with Combat-Related Polytrauma. Pain Medicine, 2009, 10, 456-469.	0.9	104
30	EFNS guideline on the drug treatment of migraine $\hat{a}\in$ " revised report of an EFNS task force. European Journal of Neurology, 2009, 16, 968-981.	1.7	649
31	Review of comorbidities and risk factors for the development of migraine complications (infarct and) Tj ETQq1	1 0.784314 1.8	rgBT /Overlo
33	Excessive opioid use and the development of chronic migraine. Pain, 2009, 142, 179-182.	2.0	88
34	Tracing transformation. Neurology, 2009, 72, S3-7.	1.5	161
35	The Face of Chronic Migraine: Epidemiology, Demographics, and Treatment Strategies. Neurologic Clinics, 2009, 27, 467-479.	0.8	20
36	Daily pharmacologic prophylaxis of episodic migraine. Techniques in Regional Anesthesia and Pain Management, 2009, 13, 20-27.	0.2	8
37	Behavioral management of headache. Techniques in Regional Anesthesia and Pain Management, 2009, 13, 50-57.	0.2	5
38	Acute Treatment of Migraine. Neurologic Clinics, 2009, 27, 417-427.	0.8	33
39	Migraine: A Question and Answer Review. Medical Clinics of North America, 2009, 93, 245-262.	1.1	8
41	Traumatic brain injury, polytrauma, and pain: Challenges and treatment strategies for the polytrauma rehabilitation Rehabilitation Psychology, 2009, 54, 247-258.	0.7	134

#	Article	IF	Citations
43	Didactic Migraine Education in US Doctor of Pharmacy Programs. American Journal of Pharmaceutical Education, 2010, 74, 4.	0.7	5
44	New therapeutic developments in chronic migraine. Current Opinion in Neurology, 2010, 23, 254-258.	1.8	21
45	Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurological Sciences, 2010, 31, 23-28.	0.9	57
46	Triptans: Where Things Stand. Current Treatment Options in Neurology, 2010, 12, 454-463.	0.7	3
47	Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurology, The, 2010, 9, 391-401.	4.9	190
48	Medication overuse headache: Neurobiological, behavioural and therapeutic aspects. Pain, 2010, 150, 222-224.	2.0	30
49	Treating Headache Recurrence After Emergency Department Discharge: A Randomized Controlled Trial of Naproxen Versus Sumatriptan. Annals of Emergency Medicine, 2010, 56, 7-17.	0.3	34
50	Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study. Cephalalgia, 2010, 30, 321-328.	1.8	112
51	Risk factors in medication-overuse headache: A 1-year follow-up study (care II protocol). Cephalalgia, 2010, 30, 329-336.	1.8	62
52	Expert Opinion: Rescue Me: Rescue Medication for Migraine. Headache, 2010, 50, 307-313.	1.8	9
53	Frequency of Headaches in Children is Influenced by Headache Status in the Mother. Headache, 2010, 50, 973-980.	1.8	32
54	What is the Role of Dependenceâ€Related Behavior in Medicationâ€Overuse Headache?. Headache, 2010, 50, 1597-1611.	1.8	73
55	NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals, 2010, 3, 1966-1987.	1.7	50
56	Headache characteristics and chronification of migraine and tension-type headache: A population-based study. Cephalalgia, 2010, 30, 943-954.	1.8	54
57	Medication overuse headache – comments on the current International Headache Society classification criteria. Cephalalgia, 2010, 30, 1409-1411.	1.8	7
58	Comments on results of Scher et al. pertaining to nonprescription caffeine-containing combination analgesics. Cephalalgia, 2010, 30, 1145-1146.	1.8	2
59	Employment and Work Impact of Chronic Migraine and Episodic Migraine. Journal of Occupational and Environmental Medicine, 2010, 52, 8-14.	0.9	148
60	Headache attributed to a substance or its withdrawal. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 589-599.	1.0	10

#	Article	IF	CITATIONS
61	Management of medication overuse headache. Drug and Therapeutics Bulletin, 2010, 48, 2-6.	0.3	7
62	Frequent headaches in the preadolescent pediatric population. Neurology, 2010, 74, 903-908.	1.5	39
63	Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain, 2010, 133, 1973-1986.	3.7	148
64	Response to †Comments on results of Scher et al. pertaining to nonprescription caffeine-containing combination analgesics'. Cephalalgia, 2010, 30, 1535-1536.	1.8	12
65	Diagnosis and Management of Chronic Daily Headache. Seminars in Neurology, 2010, 30, 154-166.	0.5	37
66	The Epidemiology of Primary Headache Disorders. Seminars in Neurology, 2010, 30, 107-119.	0.5	212
67	Acute Treatment of Migraine Headaches. Seminars in Neurology, 2010, 30, 145-153.	0.5	5
68	Triptan Therapy in Migraine. New England Journal of Medicine, 2010, 363, 63-70.	13.9	178
69	Management of Headache in the Elderly. Drugs and Aging, 2010, 27, 377-398.	1.3	27
71	Diencephalic and brainstem mechanisms in migraine. Nature Reviews Neuroscience, 2011, 12, 570-584.	4.9	454
72	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns. Neuropsychiatric Disease and Treatment, 2011, 7, 663.	1.0	22
73	Temporomandibular Disorders Are Differentially Associated With Headache Diagnoses. Clinical Journal of Pain, 2011, 27, 611-615.	0.8	153
74	What Predicts Remission from Chronic Migraine?. Neurology Today: an Official Publication of the American Academy of Neurology, 2011, 11, 8-9.	0.0	0
75	Letter to the editor concerning Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17: 1318-1325. European Journal of Neurology, 2011, 18, e80-e82.	1.7	9
76	Treatment of medication overuse headache - guideline of the EFNS headache panel. European Journal of Neurology, 2011, 18, 1115-1121.	1.7	168
77	Sexâ€Related Differences in Epidemiological and Clinicâ€Based Headache Studies. Headache, 2011, 51, 843-859.	1.8	81
78	Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS). Headache, 2011, 51, 1058-1077.	1.8	204
79	Understanding Migraine: A Tale of Hope and Frustration. Headache, 2011, 51, 1188-1190.	1.8	6

#	Article	IF	Citations
80	Chronic Migraine, Classification, Differential Diagnosis, and Epidemiology. Headache, 2011, 51, 77-83.	1.8	93
81	Which Patients With Headache Do Not Seek Medical Attention?. Headache, 2011, 51, 1279-1284.	1.8	14
82	Headache in the Emergency Department. Headache, 2011, 51, 1276-1278.	1.8	7
83	Persistent ictal-like visual cortical excitability in chronic migraine. Pain, 2011, 152, 254-258.	2.0	81
84	Update on Chronic Daily Headache. Current Treatment Options in Neurology, 2011, 13, 41-55.	0.7	33
85	Symptomatic Treatment of Migraine: When to Use NSAIDs, Triptans, or Opiates. Current Treatment Options in Neurology, 2011, 13, 15-27.	0.7	21
86	Migraine Chronification. Current Neurology and Neuroscience Reports, 2011, 11, 139-148.	2.0	81
87	Update on Medication-overuse Headache. Current Pain and Headache Reports, 2011, 15, 79-83.	1.3	43
88	Chronic Migraine: Epidemiology and Disease Burden. Current Pain and Headache Reports, 2011, 15, 70-78.	1.3	176
89	Hypervigilance or avoidance of trigger related cues in migraineurs? - A case-control study using the emotional stroop task. BMC Neurology, 2011, 11, 141.	0.8	8
90	Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?. BMC Neurology, 2011, 11, 43.	0.8	36
91	Migraine Attacks the Basal Ganglia. Molecular Pain, 2011, 7, 1744-8069-7-71.	1.0	134
92	Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology, 2011, 76, 711-718.	1.5	154
93	Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia, 2011, 31, 271-285.	1.8	358
94	Risk of Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine. Neurologist, 2011, 17, 297-299.	0.4	21
95	Genomic expression patterns in medication overuse headaches. Cephalalgia, 2011, 31, 161-171.	1.8	36
96	Medication adaptation headache. Cephalalgia, 2011, 31, 515-517.	1.8	10
98	The Cleveland Clinic Manual of Headache Therapy. , 2011, , .		6

#	Article	IF	CITATIONS
99	Triptan overuse in the Dutch general population: A nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia, 2011, 31, 943-952.	1.8	26
100	Can we help patients with chronic migraine?. Neurology, 2011, 76, 682-683.	1.5	16
101	Chronic daily headaches. Annals of Indian Academy of Neurology, 2012, 15, 40.	0.2	11
102	Headache disorders: differentiating and managing the common subtypes. British Journal of Pain, 2012, 6, 124-132.	0.7	78
103	Medication-Overuse Headache. CONTINUUM Lifelong Learning in Neurology, 2012, 18, 807-822.	0.4	40
104	Depression in headaches. Current Opinion in Neurology, 2012, 25, 277-283.	1.8	16
105	Concurrent functional and structural cortical alterations in migraine. Cephalalgia, 2012, 32, 607-620.	1.8	179
106	The Pharmacological Control of Neuronal Excitability in the Retinal Spreading Depression Model of Migraine. Current Medicinal Chemistry, 2012, 19, 298-302.	1.2	5
107	Central Nervous System Acting Drugs in Treatment of Migraine Headache. Central Nervous System Agents in Medicinal Chemistry, 2012, 12, 158-172.	0.5	9
109	Depression and risk of transformation of episodic to chronic migraine. Journal of Headache and Pain, 2012, 13, 615-624.	2.5	214
110	Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. Journal of Headache and Pain, 2012, 13, 551-555.	2.5	27
111	Brainstem 1H-MR spectroscopy in episodic and chronic migraine. Journal of Headache and Pain, 2012, 13, 645-651.	2.5	22
112	Preventive Treatment of Migraine. Headache, 2012, 52, 65-69.	1.8	10
113	The Heterogeneity of New Daily Persistent Headache. Headache, 2012, 52, 1579-1589.	1.8	22
114	Advances in Drug Development for Acute Migraine. Drugs, 2012, 72, 2187-2205.	4.9	10
115	Chronic migraine—classification, characteristics and treatment. Nature Reviews Neurology, 2012, 8, 162-171.	4.9	130
116	Treatment of Pediatric Migraine in the Emergency Room. Pediatric Neurology, 2012, 47, 233-241.	1.0	29
118	Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurological Sciences, 2012, 33, 169-171.	0.9	17

#	Article	IF	CITATIONS
119	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	2.5	129
120	Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. Journal of Headache and Pain, 2012, 13, 311-319.	2.5	70
121	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain, 2012, 13, 361-378.	2.5	248
122	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. Headache, 2012, 52, 18-36.	1.8	103
123	Chronic Morphine Increases Fosâ€Positive Neurons After Concurrent Cornea and Tail Stimulation. Headache, 2012, 52, 262-273.	1.8	6
124	Sumatriptanâ€Naproxen and Butalbital: A Doubleâ€Blind, Placeboâ€Controlled Crossover Study. Headache, 2012, 52, 530-543.	1.8	22
125	Iron Deposition in Painâ€Regulatory Nuclei in Episodic Migraine and Chronic Daily Headache by MRI. Headache, 2012, 52, 236-243.	1.8	38
126	The Case for Opiate/Opioid Therapy in the Management of Headache. Headache, 2012, 52, 35-37.	1.8	2
127	Opioids Should Not Be Used in Migraine. Headache, 2012, 52, 30-34.	1.8	61
128	Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study. Headache, 2012, 52, 1456-1470.	1.8	389
129	Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-TrÃ,ndelag Health Studies. Pain, 2012, 153, 56-61.	2.0	130
130	Defining the Differences Between Episodic Migraine and Chronic Migraine. Current Pain and Headache Reports, 2012, 16, 86-92.	1.3	211
132	Headache Frontiers: Using Magnetoencephalography to Investigate Pathophysiology of Chronic Migraine. Current Pain and Headache Reports, 2013, 17, 309.	1.3	7
133	Common hippocampal structural and functional changes in migraine. Brain Structure and Function, 2013, 218, 903-912.	1.2	136
134	Association between somatic amplification, anxiety, depression, stress and migraine. Journal of Headache and Pain, 2013, 14, 53.	2.5	56
135	Therapeutic prospects for migraine: Can paradise be regained?. Annals of Neurology, 2013, 74, 423-434.	2.8	22
136	Impact of <scp>NSAID</scp> and Triptan Use on Developing Chronic Migraine: Results From the <scp>A</scp> merican Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2013, 53, 1548-1563.	1.8	53
137	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of the Neurological Sciences, 2013, 331, 48-56.	0.3	168

#	Article	IF	CITATIONS
138	The association of dysmenorrhea with noncyclic pelvic pain accounting for psychological factors. American Journal of Obstetrics and Gynecology, 2013, 209, 422.e1-422.e10.	0.7	50
139	Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: Results of the German Headache Consortium study. Pain, 2013, 154, 484-492.	2.0	50
140	Medication Overuse Headache: History, Features, Prevention and Management Strategies. CNS Drugs, 2013, 27, 867-877.	2.7	40
141	A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurological Sciences, 2013, 34, 139-140.	0.9	6
142	Controversies in migraine treatment: opioids should be avoided. Neurological Sciences, 2013, 34, 125-128.	0.9	21
143	Opioids can be useful in the treatment of headache. Neurological Sciences, 2013, 34, 119-124.	0.9	9
144	Application of behavioral therapies in adult and adolescent patients with chronic migraine. Neurological Sciences, 2013, 34, 11-17.	0.9	11
145	Chronic Daily Headache in the Elderly. Current Pain and Headache Reports, 2013, 17, 382.	1.3	10
147	Influence of Random Measurement Error on Estimated Rates of Headache Chronification and Remission. Headache, 2013, 53, 920-929.	1.8	15
148	Medication Overuse Headaches. Medical Clinics of North America, 2013, 97, 337-352.	1.1	31
149	Refractory Migraine – A Review. Headache, 2013, 53, 599-613.	1.8	28
150	Functional Imaging in Chronic Migraine. Current Pain and Headache Reports, 2013, 17, 333.	1.3	13
151	Psychiatric comorbidities of episodic and chronic migraine. Journal of Neurology, 2013, 260, 1960-1969.	1.8	283
152	Chronic migraine. Revue Neurologique, 2013, 169, 419-426.	0.6	3
153	Calcitonin Geneâ€Related Peptide (<scp>CGRP</scp>) and Migraine Current Understanding and State of Development. Headache, 2013, 53, 1230-1244.	1.8	128
154	Migraine and childhood periodic syndromes in children and adolescents. Current Opinion in Neurology, 2013, 26, 262-268.	1.8	50
155	Death Rate From Prescription Painkillers Skyrocketed for Women Between 1999 and 2010, CDC Reports. Topics in Pain Management, 2013, 29, 8-10.	0.1	0
157	Florida Pain Physicians Convicted of Money Laundering, Acquitted of Conspiracy to Distribute Drugs. Topics in Pain Management, 2013, 29, 12.	0.1	0

#	Article	IF	CITATIONS
158	Medication-overuse headache. Current Opinion in Neurology, 2013, 26, 276-281.	1.8	41
159	Medication Overuse Headache. Topics in Pain Management, 2013, 29, 1-7.	0.1	2
160	Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia, 2013, 33, 52-64.	1.8	46
161	Incidence and Risk Factors of Chronic Daily Headache in Young Adolescents: A School Cohort Study. Pediatrics, 2013, 132, e9-e16.	1.0	49
163	Neuromagnetic Abnormality of Motor Cortical Activation and Phases of Headache Attacks in Childhood Migraine. PLoS ONE, 2013, 8, e83669.	1.1	15
164	Migren Akut Tedavisi. Noropsikiyatri Arsivi, 2013, 50, 26-29.	0.7	6
165	Kronik Migrenin Aydınlanmaya Başlayan Yýzü. Noropsikiyatri Arsivi, 2013, 50, 21-25.	0.7	5
166	Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention (<scp>AMPP</scp>) Study. Headache, 2013, 53, 1300-1311.	1.8	128
167	Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans. Headache, 2013, 53, 1415-1429.	1.8	21
168	Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. European Journal of Neurology, 2013, 20, 655-662.	1.7	9
169	Rounding Behavior in the Reporting of Headache Frequency Complicates Headache Chronification Research. Headache, 2013, 53, 908-919.	1.8	25
171	Rethinking Headache Chronification. Headache, 2013, 53, 901-907.	1.8	20
172	A Retrospective Matched Case-Control Study on Medical Costs of Refractory Migraine in Taiwan. Headache, 2013, 53, 526-539.	1.8	8
173	Choosing Wisely in Headache Medicine: The <scp>A</scp> merican Headache Society's List of Five Things Physicians and Patients Should Question. Headache, 2013, 53, 1651-1659.	1.8	150
174	Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert Review of Neurotherapeutics, 2013, 13, 1041-1059.	1.4	18
175	Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. Canadian Journal of Neurological Sciences, 2013, 40, s33-s62.	0.3	2
176	Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient. Canadian Journal of Neurological Sciences, 2013, 40, S33-S62.	0.3	4
178	Latin American consensus on guidelines for chronic migraine treatment. Arquivos De Neuro-Psiquiatria, 2013, 71, 478-486.	0.3	25

#	Article	IF	Citations
179	Preventive treatment in migraine and the new US guidelines. Neuropsychiatric Disease and Treatment, 2013, 9, 709.	1.0	87
180	Chronic daily headache., 0,, 95-105.		0
181	Tackling chronic migraine: current perspectives. Journal of Pain Research, 2014, 7, 185.	0.8	29
182	Migraine Attack Treatment: A Tailor-made Suit, Not One Size Fits All. Recent Patents on CNS Drug Discovery, 2014, 9, 26-40.	0.9	12
183	Pediatric migraine and episodic syndromes that may be associated with migraine. Italian Journal of Pediatrics, 2014, 40, 92.	1.0	31
185	Cefalea por abuso de medicaci \tilde{A}^3 n. FMC Formacion Medica Continuada En Atencion Primaria, 2014, 21, 603-605.	0.0	0
186	Eager for better migraine therapies. Neurology, 2014, 83, 954-955.	1.5	1
187	Trigger Factors and Premonitory Features of Migraine Attacks: Summary of Studies. Headache, 2014, 54, 1670-1679.	1.8	111
188	Should Butalbital Ever Be Given, Much Less to a Pregnant Woman?. Headache, 2014, 54, 10-11.	1.8	6
189	Clinical Aspects of Medication Overuse Headaches. Headache, 2014, 54, 211-217.	1.8	47
190	<scp>SumaRT</scp> / <scp>N</scp> ap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study. Headache, 2014, 54, 67-79.	1.8	12
191	Correlation of Headache Frequency and Psychosocial Impairment in Migraine: A Crossâ€Sectional Study. Headache, 2014, 54, 861-871.	1.8	22
192	Opioids in Headache. Headache, 2014, 54, 12-21.	1.8	47
193	Medication Overuse Headache. Headache, 2014, 54, 203-203.	1.8	0
194	Consensus treatment of medication overuse headache in Latin America and Europe. Cephalalgia, 2014, 34, 643-644.	1.8	2
196	Outcomes of Greater Occipital Nerve Injections in Pediatric Patients With Chronic Primary Headache Disorders. Pediatric Neurology, 2014, 50, 135-139.	1.0	52
197	Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia, 2014, 34, 594-604.	1.8	62
198	Targeting TRP Channels For Novel Migraine Therapeutics. ACS Chemical Neuroscience, 2014, 5, 1085-1096.	1.7	77

#	Article	IF	CITATIONS
200	Treatment of Chronic Migraine: A 3â€Month Comparator Study of Naproxen Sodium vs <scp>SumaRT</scp> / <scp>N</scp> ap. Headache, 2014, 54, 80-93.	1.8	17
201	Considerations in the Treatment of Tension-Type Headache in the Elderly. Drugs and Aging, 2014, 31, 797-804.	1.3	7
203	Vestibular Migraine and Related Syndromes. , 2014, , .		5
204	Allodynia is associated with a higher prevalence of depression in migraine patients. Cephalalgia, 2014, 34, 1187-1192.	1.8	32
205	Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health and Quality of Life Outcomes, 2014, 12, 117.	1.0	109
206	Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 2014, 83, 958-966.	1.5	235
208	Chronic migraine. BMJ, The, 2014, 348, g1416-g1416.	3.0	187
209	Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Quality of Life Research, 2014, 23, 1273-1277.	1.5	25
210	Medication Overuse in Children and Adolescents. Current Pain and Headache Reports, 2014, 18, 428.	1.3	39
211	The Cleveland Clinic Manual of Headache Therapy. , 2014, , .		4
213	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headacheâ€Related Disability: Results From the American Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2015, 55, 825-839.	1.8	20
215	Migraine incidence in 5Âyears: a population-based prospective longitudinal study in Turkey. Journal of Headache and Pain, 2015, 16, 103.	2.5	29
216	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. Human Genomics, 2015, 9, 30.	1.4	7
217	Wisely Evaluating and Managing Headaches. Headache, 2015, 55, 1299-1300.	1.8	0
218	Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Pilot Trial of Efficacy and Safety. Headache, 2015, 55, 1192-1208.	1.8	13
219	Persistent Frequent Nausea Is Associated With Progression to Chronic Migraine: <scp>AMPP</scp> Study Results. Headache, 2015, 55, 76-87.	1.8	46
221	Use of aspirin combinations with caffeine and increasing headache frequency. Pain, 2015, 156, 1747-1754.	2.0	9
222	Headache and migraine. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 131, 447-463.	1.0	35

#	Article	IF	Citations
223	Occipital Nerve Stimulation for Chronic Migraineâ€"A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0116786.	1.1	60
224	Study of the use of analgesics by patients with headache at a specialized outpatient clinic (ACEF). Arquivos De Neuro-Psiquiatria, 2015, 73, 586-592.	0.3	8
225	Acute and Preventative Treatment of Episodic Migraine. , 2015, , 69-97.		1
226	Improving Medication Adherence in Migraine Treatment. Current Pain and Headache Reports, 2015, 19, 24.	1.3	37
227	Too Much of a Good Thing. , 2015, , 253-266.		0
228	Best Practices for Patients With Chronic Migraine. Mayo Clinic Proceedings, 2015, 90, 408-414.	1.4	33
229	Convincing the skeptic. How to fix emergency department headache management. Cephalalgia, 2015, 35, 641-643.	1.8	6
230	The diagnosis and treatment of chronic migraine. Therapeutic Advances in Chronic Disease, 2015, 6, 115-123.	1.1	119
231	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 99-102.	1.8	1
232	Therapeutic applications of botulinum neurotoxins in head and neck disorders. Saudi Dental Journal, 2015, 27, 3-11.	0.5	12
233	Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA. Applied Health Economics and Health Policy, 2015, 13, 109-120.	1.0	3
234	Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache, 2015, 55, 103-122.	1.8	227
235	Effectiveness in acute migraine treatment. Neurology, 2015, 84, 641-642.	1.5	0
236	Chronic migraine with medication overuse: Association between disability and quality of life measures, and impact of disease on patients' lives. Journal of the Neurological Sciences, 2015, 348, 60-66.	0.3	34
237	Part Ilâ€"Management of Pediatric Post-traumatic Headaches. Pediatric Neurology, 2015, 52, 270-280.	1.0	37
238	Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people. Cephalalgia, 2015, 35, 1172-1180.	1.8	22
239	Medication overuse and chronic migraine: a critical review according to clinical pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1127-1144.	1.5	27
240	Costo beneficio del tratamiento de la migra $ ilde{A}$ ±a cr $ ilde{A}$ ³nica con Onabotulinumtoxin A en Argentina. Neurologia Argentina, 2015, 7, 84-88.	0.1	0

#	Article	IF	CITATIONS
241	Approaches to treatments of chronic migraine associated with medication overuse: a comparison between different intensity regimens. Neurological Sciences, 2015, 36, 5-8.	0.9	7
242	Medication-overuse headache in China: Clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia, 2015, 35, 644-651.	1.8	25
243	Butalbital and Pediatric Headache: Stay off the Downward Path. Headache, 2015, 55, 327-330.	1.8	3
244	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 2015, 84, 688-695.	1.5	219
245	Risk Factors of Chronic Daily Headache or Chronic Migraine. Current Pain and Headache Reports, 2015, 19, 465.	1.3	53
246	Current management of migraine in US emergency departments: An analysis of the National Hospital Ambulatory Medical Care Survey. Cephalalgia, 2015, 35, 301-309.	1.8	79
247	Gender differences in older adults with chronic migraine in <scp>T</scp> urkey. Geriatrics and Gerontology International, 2015, 15, 652-658.	0.7	7
248	No Microstructural White Matter Alterations in Chronic and Episodic Migraineurs: A Case–Control Diffusion Tensor Magnetic Resonance Imaging Study. Headache, 2015, 55, 241-251.	1.8	44
249	Are Depressive Symptomatology, Selfâ€Efficacy, and Perceived Social Support Related to Disability and Quality of Life in Patients With Chronic Migraine Associated to Medication Overuse? Data From a Crossâ€Sectional Study. Headache, 2015, 55, 636-645.	1.8	27
250	Are Episodic and Chronic Migraine One Disease or Two?. Current Pain and Headache Reports, 2015, 19, 53.	1.3	10
251	Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clinical Medicine, 2015, 15, 344-350.	0.8	58
252	Medication Overuse Headache. Current Neurology and Neuroscience Reports, 2015, 15, 509.	2.0	21
253	Abnormal cortical activation in females with acute migraine: A magnetoencephalography study. Clinical Neurophysiology, 2015, 126, 170-179.	0.7	17
254	Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. Acta Neurologica Belgica, 2015, 115, 1-17.	0.5	15
255	Delta-opioid receptors as targets for migraine therapy. Current Opinion in Neurology, 2016, 29, 314-319.	1.8	27
256	How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache, 2016, 56, 1194-1200.	1.8	21
257	Medication-overuse headache: a perspective review. Therapeutic Advances in Drug Safety, 2016, 7, 147-158.	1.0	35
258	Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology, 2016, 12, 455-464.	4.9	391

#	ARTICLE	IF	CITATIONS
259	Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache. Annals of Neurology, 2016, 79, 1000-1013.	2.8	68
260	How Well Does the ICHD 3 (Beta) Help in Real-Life Migraine Diagnosis and Management?. Current Pain and Headache Reports, 2016, 20, 66.	1.3	10
261	Clinician's Manual on Migraine. , 2016, , .		1
262	Prevalence of personality disorders in patients with chronic migraine. Comprehensive Psychiatry, 2016, 68, 60-64.	1.5	17
263	Phenotypic features of chronic migraine. Journal of Headache and Pain, 2016, 17, 26.	2.5	21
264	Women with Chronic and Episodic Migraine Exhibit Similar Widespread Pressure Pain Sensitivity. Pain Medicine, 2016, 17, 2127-2133.	0.9	42
265	Predicting Inadequate Response to Acute Migraine Medication: Results From the <scp>A</scp> merican Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2016, 56, 1635-1648.	1.8	64
266	Chronic Migraine Is Associated With Sustained Elevation of Somatosensory Temporal Discrimination Thresholds. Headache, 2016, 56, 1439-1447.	1.8	22
267	39 Literatur. , 2016, , .		0
268	Headache. Seminars in Neurology, 2016, 36, 442-448.	0.5	1
268 269	Headache. Seminars in Neurology, 2016, 36, 442-448. Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91.	0.5	36
	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study.		
269	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache, 2016, 56,	1.7	36
269 270	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache, 2016, 56, 49-70. Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control. Headache, 2016, 56,	1.7	36 58
269 270 271	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache, 2016, 56, 49-70. Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control. Headache, 2016, 56, 1675-1684. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. Journal of Headache and	1.7 1.8 1.8	36 58 10
269 270 271 272	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache, 2016, 56, 49-70. Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control. Headache, 2016, 56, 1675-1684. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. Journal of Headache and Pain, 2016, 17, 85.	1.7 1.8 1.8	36 58 10
269 270 271 272 273	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache, 2016, 56, 49-70. Chronic Daily Headache: Ten Steps for Primary Care Providers to Regain Control. Headache, 2016, 56, 1675-1684. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. Journal of Headache and Pain, 2016, 17, 85. Migraine. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 138, 283-293. Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurological	1.7 1.8 1.8 2.5	36 58 10 7

#	Article	IF	CITATIONS
277	Dural stimulation in rats causes brain-derived neurotrophic factor–dependent priming to subthreshold stimuli including a migraine trigger. Pain, 2016, 157, 2722-2730.	2.0	45
278	Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience, 2016, 338, 130-144.	1.1	119
279	Patients with chronic, but not episodic, migraine display altered activity of their neck extensor muscles. Journal of Electromyography and Kinesiology, 2016, 30, 66-72.	0.7	35
280	Chronic Migraine in Children and Adolescents. Current Pain and Headache Reports, 2016, 20, 14.	1.3	17
281	Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia, 2016, 36, 1324-1333.	1.8	101
282	Blood gene expression studies in migraine: Potential and caveats. Cephalalgia, 2016, 36, 669-678.	1.8	19
283	Diagnosis and Management of Childhood Headache. Current Problems in Pediatric and Adolescent Health Care, 2016, 46, 36-51.	0.8	31
284	Migraine and its psychiatric comorbidities. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 741-749.	0.9	298
285	Update on the Pharmacological Treatment of Chronic Migraine. Current Pain and Headache Reports, 2016, 20, 6.	1.3	32
286	Impulsividad en pacientes migrañosos: estudio en una serie de 155 casos. NeurologÃa, 2016, 31, 599-605.	0.3	10
287	Drug Treatment for Episodic and Chronic Tension-Type Headache. Headache, 2016, , 89-99.	0.2	2
289	Treatment of medication-overuse headache: A systematic review. Cephalalgia, 2016, 36, 371-386.	1.8	148
290	Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. Cephalalgia, 2017, 37, 864-872.	1.8	90
291	When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia, 2017, 37, 104-113.	1.8	68
292	Association Between Severity of Temporomandibular Disorders and the Frequency of Headache Attacks in Women With Migraine: A Cross-Sectional Study. Journal of Manipulative and Physiological Therapeutics, 2017, 40, 250-254.	0.4	20
293	Treatment Update of Chronic Migraine. Current Pain and Headache Reports, 2017, 21, 26.	1.3	37
294	An Algorithm for Opioid and Barbiturate Reduction in the Acute Management of Headache in the Emergency Department. Headache, 2017, 57, 71-79.	1.8	13
295	The Delta Opioid Receptor in Pain Control. Handbook of Experimental Pharmacology, 2017, 247, 147-177.	0.9	21

#	Article	IF	Citations
296	Extracranial origin of headache. Current Opinion in Neurology, 2017, 30, 263-271.	1.8	54
297	The Number of Active But Not Latent Trigger Points Associated with Widespread Pressure Pain Hypersensitivity in Women with Episodic Migraines. Pain Medicine, 2017, 18, 2485-2491.	0.9	11
298	The Effectiveness of Treatments for Patients With Medication Overuse Headache: A Systematic Review and Meta-Analysis. Journal of Pain, 2017, 18, 615-627.	0.7	48
299	Structural Gray Matter Alterations in Chronic Migraine: Implications for a Progressive Disease?. Headache, 2017, 57, 400-416.	1.8	75
300	Primary Headaches in an Elderly Population Seeking Medical Care for Cognitive Decline. Headache, 2017, 57, 209-216.	1.8	15
301	Pharmacological Treatment of Headache and Comorbidities. Headache, 2017, , 209-222.	0.2	0
302	Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology, 2017, 89, 2075-2082.	1.5	58
303	Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States. Headache, 2017, 57, 1399-1408.	1.8	57
304	Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain. BMJ Open, 2017, 7, e017851.	0.8	23
305	Primary Headache Disorders- Part 2: Tension-type headache and medication overuse headache. Disease-a-Month, 2017, 63, 342-367.	0.4	20
306	Medication overuse headache. Neurology, 2017, 89, 1296-1304.	1.5	58
307	Migrainomics — identifying brain and genetic markers of migraine. Nature Reviews Neurology, 2017, 13, 725-741.	4.9	37
308	CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs, 2017, 31, 487-501.	2.2	45
309	Caffeine in the management of patients with headache. Journal of Headache and Pain, 2017, 18, 107.	2.5	73
310	Comorbid pain and migraine chronicity. Neurology, 2017, 89, 461-468.	1.5	61
311	Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurological Sciences, 2017, 38, 3-6.	0.9	21
313	What to Try When Nothing's Working. , 2017, , 135-191.		0
314	Predictors of 12â€Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache, 2017, 57, 60-70.	1.8	38

#	ARTICLE	IF	Citations
315	Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurology, The, 2017, 16, 76-87.	4.9	424
316	Risk perception of NSAIDs in hospitalized patients in Greece. Bratislava Medical Journal, 2017, 118, 427-430.	0.4	5
317	Migraine and Complex Regional Pain Syndrome: A Case-Referent Clinical Study. BioMed Research International, 2017, 2017, 1-8.	0.9	2
318	Childhood Headache: A Brief Review. Pediatric Annals, 2017, 46, e155-e165.	0.3	34
319	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. Journal of Headache and Pain, 2017, 18, 101.	2.5	158
320	Headache of Analgesic Abuse as a Cause of New Pain Pathways Development. , 2017, , .		0
321	Migraine. Lancet, The, 2018, 391, 1315-1330.	6.3	327
322	Early management of patients with medicationâ€overuse headache: results from a multicentre clinical study. European Journal of Neurology, 2018, 25, 1027-1033.	1.7	7
323	Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia, 2018, 38, 2045-2057.	1.8	27
324	Benign Headache Management in the Emergency Department. Journal of Emergency Medicine, 2018, 54, 458-468.	0.3	27
325	Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia, 2018, 38, 1841-1848.	1.8	18
326	Diagnosis and Management of Headache in Older Adults. Mayo Clinic Proceedings, 2018, 93, 252-262.	1.4	34
327	Longitudinal assessment of gray matter volumes and white matter integrity in patients with medication-overuse headache. Neuroradiology Journal, 2018, 31, 150-156.	0.6	4
328	Fundamentals of Pain Medicine. , 2018, , .		5
329	Secondary Headaches., 2018,, 291-300.		1
330	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	1.4	24
331	Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting. Drugs and Therapy Perspectives, 2018, 34, 335-343.	0.3	4
332	Association of neurologist care with headache expenditures: A population-based, longitudinal analysis. Cephalalgia, 2018, 38, 1876-1884.	1.8	3

#	Article	IF	CITATIONS
333	La migraine chroniqueÂ: du concept à la prise en charge thérapeutique. Pratique Neurologique - FMC, 2018, 9, 105-110.	0.1	0
334	Opioid-Induced "Likeability―and "Feeling Good―Are Not Associated With Return Visits to an ED Among Migraine Patients Administered IV Hydromorphone. Headache, 2018, 58, 750-754.	1.8	4
335	The Migraine Attack as a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory. Headache, 2018, 58, 118-135.	1.8	49
336	Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiology and Drug Safety, 2018, 27, 495-503.	0.9	30
337	Headache highlights 2017. Cephalalgia Reports, 2018, 1, 251581631877377.	0.2	0
338	The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache, 2019, 59, 1-18.	1.8	390
339	Migraine and Tension-Type Headache. Seminars in Neurology, 2018, 38, 608-618.	0.5	29
340	Triggers, Protectors, and Predictors in Episodic Migraine. Current Pain and Headache Reports, 2018, 22, 81.	1.3	105
341	A Short Review of the Treatment of Headaches Using Osteopathic Manipulative Treatment. Current Pain and Headache Reports, 2018, 22, 82.	1.3	4
342	Comprehensive review and update on chronic migraine. Journal of the Korean Medical Association, 2018, 61, 314.	0.1	1
343	Diagnosis and Treatment of Primary Headache Disorders in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 2408-2416.	1.3	13
344	Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine. Headache, 2018, 58, 1579-1592.	1.8	61
346	Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. Current Pain and Headache Reports, 2018, 22, 71.	1.3	13
347	Animal Models of Chronic Migraine. Current Pain and Headache Reports, 2018, 22, 44.	1.3	21
348	Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns. Pain, 2018, 159, 1980-1988.	2.0	24
349	Effects of a Physical Therapy Protocol in Patients with Chronic Migraine and Temporomandibular Disorders: A Randomized, Single-Blinded, Clinical Trial. Journal of Oral and Facial Pain and Headache, 2018, 32, 137-150.	0.7	43
350	Nonsurgical Management of Migraine. , 2018, , 391-402.		0
351	Diagnosis and Management of Head and Face Pain. , 2018, , .		1

#	Article	IF	CITATIONS
352	Use and overuse of triptans in Austria $\hat{a} \in \hat{a}$ a survey based on nationwide healthcare claims data. Journal of Headache and Pain, 2018, 19, 34.	2.5	17
353	Effects of systemic inhibitors of acidâ€sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine. British Journal of Pharmacology, 2018, 175, 4154-4166.	2.7	41
354	Paediatric migraine: evidence-based management and future directions. Nature Reviews Neurology, 2018, 14, 515-527.	4.9	36
355	Health Behaviors in Episodic Migraine: Why Behavior Change Matters. Current Pain and Headache Reports, 2018, 22, 65.	1.3	20
356	Medication-overuse headache: a widely recognized entity amidst ongoing debate. Journal of Headache and Pain, 2018, 19, 50.	2.5	110
357	What Is Migraine?. , 2018, , 7-30.		1
358	Does myofascial and trigger point treatment reduce pain and analgesic intake in patients undergoing onabotulinumtoxinA injection due to chronic intractable migraine?. European Journal of Physical and Rehabilitation Medicine, 2018, 54, 1-12.	1.1	24
359	Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. Journal of Headache and Pain, 2018, 19, 73.	2.5	25
360	Primary Headaches. Dental Clinics of North America, 2018, 62, 611-628.	0.8	23
361	The role of personality, disability and physical activity in the development of medication-overuse headache: a prospective observational study. Journal of Headache and Pain, 2018, 19, 39.	2.5	15
362	Opioid Use Among Patients Presenting with Migraine in the Emergency Department. Value in Health, 2018, 21, S210.	0.1	0
363	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2018, 19, 38.	2.5	88
364	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.5	186
365	Migraine Care Challenges and Strategies in US Uninsured and Underinsured Adults: A Narrative Review, Part 2. Headache, 2018, 58, 633-647.	1.8	10
366	Linking migraine frequency with family history of migraine. Cephalalgia, 2019, 39, 229-236.	1.8	30
367	The long and winding road: the journey taken by headache sufferers in search of help. Primary Health Care Research and Development, 2019, 20, e4.	0.5	16
368	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Neurology, 2019, 93, 487-499.	1.5	103
369	Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200. Pain Research and Management, 2019, 2019, 1-9.	0.7	15

#	Article	IF	CITATIONS
370	Medication Overuse and Medication Overuse Headache: Risk Factors, Comorbidities, Associated Burdens and Nonpharmacologic and Pharmacologic Treatment Approaches. Current Pain and Headache Reports, 2019, 23, 60.	1.3	16
371	A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. Journal of Headache and Pain, 2019, 20, 74.	2.5	32
372	Emerging evidence of occipital nerve compression in unremitting head and neck pain. Journal of Headache and Pain, 2019, 20, 76.	2.5	35
373	Impact of chronic migraine attacks and their severity on the endogenous $\hat{l}\frac{1}{4}$ -opioid neurotransmission in the limbic system. NeuroImage: Clinical, 2019, 23, 101905.	1.4	26
374	Migraine. Neurologic Clinics, 2019, 37, 631-649.	0.8	358
375	Preventive Treatment for Episodic Migraine. Neurologic Clinics, 2019, 37, 753-770.	0.8	29
376	Migraine in the Emergency Department. Neurologic Clinics, 2019, 37, 743-752.	0.8	5
377	Acute Treatment of Migraine. Neurologic Clinics, 2019, 37, 727-742.	0.8	17
378	Migraine Headache: An Underâ€Appreciated Risk Factor for Cardiovascular Disease in Women. Journal of the American Heart Association, 2019, 8, e014546.	1.6	23
379	Pediatric Migraine. Neurologic Clinics, 2019, 37, 815-833.	0.8	22
380	Practice guideline update summary: Acute treatment of migraine in children and adolescents. Headache, 2019, 59, 1158-1173.	1.8	25
381	Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 1762-1772.	1.8	31
382	Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort. Headache, 2019, 59, 1481-1491.	1.8	15
383	Clinical practice guideline for chronic headache 2013. Neurology and Clinical Neuroscience, 2019, 7, 231-259.	0.2	17
384	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	2.5	116
385	KAMST – Simple method for patients with migraine screening. Medical Hypotheses, 2019, 128, 21-24.	0.8	2
386	Migraine: Experimental Models and Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2019, 20, 2932.	1.8	37
387	<p>Peripheral nerve field stimulation to the preauricular area for intractable chronic migraine: a case report</p> . Journal of Pain Research, 2019, Volume 12, 1665-1671.	0.8	1

#	Article	IF	CITATIONS
388	Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurology, The, 2019, 18, 891-902.	4.9	151
389	Periodontal inflammation is related to increased serum calcitonin geneâ€related peptide levels in patients with chronic migraine. Journal of Periodontology, 2019, 90, 1088-1095.	1.7	23
390	Acupuncture Reversible Effects on Altered Default Mode Network of Chronic Migraine Accompanied with Clinical Symptom Relief. Neural Plasticity, 2019, 2019, 1-10.	1.0	41
391	The Association between Chronicity of Migraine and Complementary and Alternative Medication Use: The Turkish Perspective. European Neurology, 2019, 81, 24-29.	0.6	4
392	Episodic and Chronic Migraine in Primary Care. Headache, 2019, 59, 1042-1051.	1.8	21
393	The burden of headache disorders in the Eastern Mediterranean Region, 1990-2016: findings from the Global Burden of Disease study 2016. Journal of Headache and Pain, 2019, 20, 40.	2.5	22
394	The Effectiveness of Acupuncture Combined with Tuina Therapy in Patients with Migraine. Complementary Medicine Research, 2019, 26, 182-194.	0.5	13
395	Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia, 2019, 39, 1086-1098.	1.8	25
396	Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache, 2019, 59, 880-890.	1.8	36
397	Imaging of Headache. , 2019, , 41-75.		0
398	Real-world insights on the management of migraine patients: an Italian nationwide study. Current Medical Research and Opinion, 2019, 35, 1545-1554.	0.9	11
399	Unmet Needs in Headache Management. Headache, 2019, , 13-25.	0.2	1
400	Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data. Cephalalgia, 2019, 39, 1000-1009.	1.8	7
401	Placebos and Nocebos in Headaches. Headache, 2019, , .	0.2	4
402	Factores predictores de la calidad del sueño en pacientes con migraña crónica. NeurologÃa, 2019, , .	0.3	3
403	Migraine progression in subgroups of migraine based on comorbidities. Neurology, 2019, 93, e2224-e2236.	1.5	60
404	Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine. JAMA - Journal of the American Medical Association, 2019, 322, 1887.	3.8	193
405	Headache in the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 511-528.	1.0	12

#	Article	IF	Citations
406	Cognitive Biases & Errors in Headache Medicine. Headache, 2019, 59, 1863-1870.	1.8	2
407	Complementary and Integrative Health Treatments for Migraine. Journal of Neuro-Ophthalmology, 2019, 39, 360-369.	0.4	14
408	From Episodic to Chronic: A Discussion on Headache Transformation. , 2019, , 313-320.		0
409	Chronic Migraine: Epidemiology, Mechanisms, and Treatment., 2019,, 37-62.		1
410	Migraine Progression: A Systematic Review. Headache, 2019, 59, 306-338.	1.8	198
411	Migraine Treatment in Pregnant Women Presenting to Acute Care: A Retrospective Observational Study. Headache, 2019, 59, 173-179.	1.8	9
412	Clinical Features Contributing to Cortical Thickness Changes in Chronic Migraine – A Pilot Study. Headache, 2019, 59, 180-191.	1.8	22
413	The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Postâ€Hoc Analyses on the First 3 Weeks of Treatment. Headache, 2019, 59, 383-393.	1.8	32
414	Chronic Daily Headache Classification. , 2019, , 357-381.		0
415	Migraine and Tension-Type Headache. Medical Clinics of North America, 2019, 103, 215-233.	1.1	75
416	Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia, 2019, 39, 617-625.	1.8	26
417	Opioid free treatment algorithm for ED headache management: Effect on revisit rate. American Journal of Emergency Medicine, 2020, 38, 28-32.	0.7	6
418	Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs. Clinical Oral Investigations, 2020, 24, 597-606.	1.4	15
419	Increased epicardial fat thickness and carotid intima–media thickness in migraine patients. Neurological Sciences, 2020, 41, 49-56.	0.9	5
420	The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patientâ€derived data. European Journal of Neurology, 2020, 27, 62.	1.7	27
421	Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. Cephalalgia, 2020, 40, 503-516.	1.8	43
422	Celecoxib reduces cortical spreading depression–induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks. Pain, 2020, 161, 1019-1026.	2.0	7
423	Headache Hygiene in Pediatrics: Brushing Up on the Basics. Pediatric Neurology, 2020, 103, 3-7.	1.0	5

#	Article	IF	Citations
424	Experimentally induced spinal nociceptive sensitization increases with migraine frequency: a single-blind controlled study. Pain, 2020, 161, 429-438.	2.0	11
425	Epidemiology and determinants of chronic migraine: A real-world cohort study, with nested case-control analysis, in primary care in Italy. Cephalalgia, 2020, 40, 461-469.	1.8	5
426	Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and) Tj ETQq0 0 0 rg	gB E/ Overl	oc ls 1 10 Tf 50 6
427	The Health and Productivity Burden of Migraines in Australia. Headache, 2020, 60, 2291-2303.	1.8	10
428	The impact of midlife on migraine in women: summary of current views. Women's Midlife Health, 2020, 6, 11.	0.5	9
429	Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment. Journal of Primary Care and Community Health, 2020, 11, 215013272095993.	1.0	4
430	Quality improvement in neurology. Neurology, 2020, 95, 866-873.	1.5	12
431	Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. Journal of Headache and Pain, 2020, 21, 115.	2.5	86
432	Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database. Journal of Medical Economics, 2020, 23, 1356-1364.	1.0	8
434	Patterns and predictors of opioid use among migraine patients at emergency departments: A retrospective database analysis. Cephalalgia, 2020, 40, 1489-1501.	1.8	9
435	Differential medication overuse risk of novel anti-migraine therapeutics. Brain, 2020, 143, 2681-2688.	3.7	37
436	Role of greater occipital nerve block for preventive treatment of chronic migraine: A critical review. Cephalalgia Reports, 2020, 3, 251581632096440.	0.2	5
437	Recruitment, retention, and adherence in a randomized feasibility trial of mindfulness-based stress reduction for patients with migraine. Complementary Therapies in Medicine, 2020, 55, 102610.	1.3	6
438	Acute treatment of migraine in children and adolescents: review of the American Academy of Neurology Practice guideline update. Archives of Disease in Childhood: Education and Practice Edition, 2020, 106, edpract-2019-318580.	0.3	1
439	European Academy of Neurology guideline on the management of medicationâ€overuse headache. European Journal of Neurology, 2020, 27, 1102-1116.	1.7	69
440	Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. Journal of Headache and Pain, 2020, 21, 53.	2.5	20
441	Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments. Expert Review of Neurotherapeutics, 2020, 20, 591-600.	1.4	17
442	Characterizing opioid use in a US population with migraine. Neurology, 2020, 95, e457-e468.	1.5	48

#	Article	IF	CITATIONS
443	Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Medicine in Drug Discovery, 2020, 7, 100053.	2.3	15
444	Machine learning approach to predict medication overuse in migraine patients. Computational and Structural Biotechnology Journal, 2020, 18, 1487-1496.	1.9	23
445	The cerebellum is associated with 2-year prognosis in patients with high-frequency migraine. Journal of Headache and Pain, 2020, 21, 29.	2.5	21
446	Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 903-912.	1.8	24
447	Estimating the savings associated with a migraineâ€free life: results from the Spanish Atlas. European Journal of Neurology, 2020, 27, 2616-2624.	1.7	17
448	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia, 2020, 40, 892-902.	1.8	47
449	Outâ€ofâ€hospital assessment and treatment of adults with atraumatic headache. Journal of the American College of Emergency Physicians Open, 2020, 1, 17-23.	0.4	1
450	Evidence Regarding Medication Overuse Headache in Children and Adolescents: Protocol for a Systematic Review. Headache, 2020, 60, 171-177.	1.8	7
451	The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. Science Translational Medicine, 2020, 12, .	5.8	46
452	Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study. Cephalalgia, 2020, 40, 1070-1078.	1.8	6
453	An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain and Therapy, 2020, 9, 195-215.	1.5	17
454	The Many Faces of Medicationâ€Overuse Headache in Clinical Practice. Headache, 2020, 60, 1021-1036.	1.8	9
455	Quality Improvement in Neurology: Headache Quality Measurement Set. Headache, 2021, 61, 219-226.	1.8	6
456	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia, 2021, 41, 6-16.	1.8	25
457	Reversion from chronic migraine to episodic migraine: A new outcome measure. Cephalalgia, 2021, 41, 3-5.	1.8	0
458	The Prevalence of Opioid Analgesic Use in People with Chronic Noncancer Pain: Systematic Review and Meta-Analysis of Observational Studies. Pain Medicine, 2021, 22, 506-517.	0.9	11
459	How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia, 2021, 41, 613-630.	1.8	18
460	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. Headache, 2021, 61, 103-116.	1.8	10

#	Article	IF	CITATIONS
461	Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists. Drugs and Therapy Perspectives, 2021, 37, 75-86.	0.3	3
462	Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia, 2021, 41, 443-452.	1.8	5
463	Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Quality of Life Research, 2021, 30, 105-115.	1,5	14
464	Current clinical practice in disabling and chronic migraine in the primary care setting: results from the European My-LIFE anamnesis survey. BMC Neurology, 2021, 21, 1.	0.8	76
465	Advances in the Understanding of Pathophysiology of TTH and its Management. Neurology India, 2021, 69, 116.	0.2	9
466	Chronic migraine: Genetics or environment?. European Journal of Neurology, 2021, 28, 1726-1736.	1.7	10
467	Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache. Pain, 2021, Publish Ahead of Print, 2246-2262.	2.0	11
468	Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study. Cephalalgia Reports, 2021, 4, 251581632110400.	0.2	2
469	Comprehensive management of adults with chronic migraine: Clinical practice guidelines in Mexico. Cephalalgia Reports, 2021, 4, 251581632110339.	0.2	0
470	Headache for ophthalmologists: current advances in headache understanding and management. Eye, 2021, 35, 1574-1586.	1.1	7
471	Predictive factors of sleep quality in patients with chronic migraine. NeurologÃa (English Edition), 2022, 37, 101-109.	0.2	6
472	Impact of emergency department opioid use on future health resource utilization among patients with migraine. Headache, 2021, 61, 287-299.	1.8	9
473	Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurology and Therapy, 2021, 10, 235-249.	1.4	14
474	Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine. Headache, 2021, 61, 229-230.	1.8	1
476	An Evaluation of Medication Prescribing Patterns for Acute Migraine in the Emergency Department: A Scoping Review. Journal of Clinical Medicine, 2021, 10, 1191.	1.0	5
477	Pediatric Episodic Migraine with Aura: A Unique Entity?. Children, 2021, 8, 228.	0.6	3
478	Need of guidance in disabling and chronic migraine identification in the primary care setting, results from the european MyLife anamnesis survey. BMC Family Practice, 2021, 22, 54.	2.9	5
479	Medication overuse headache. Current Opinion in Neurology, 2021, 34, 378-383.	1.8	4

#	Article	IF	CITATIONS
480	Acute migraine management in the emergency department: experience from a large Spanish tertiary hospital. Internal and Emergency Medicine, 2021, 16, 2243-2249.	1.0	1
481	Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin geneâ€'related peptideâ€targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drugâ€"drug interaction study. Headache, 2021, 61, 642-652.	1.8	37
482	Chronic headaches and middle meningeal artery embolization. Journal of NeuroInterventional Surgery, 2022, 14, 301-303.	2.0	6
483	Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020. Journal of Headache and Pain, 2021, 22, 22.	2.5	25
484	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Review of Neurotherapeutics, 2021, 21, 491-502.	1.4	6
485	Matchingâ€adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and healthâ€related quality of life in the treatment of migraine. Headache, 2021, 61, 906-915.	1.8	8
486	The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. CNS Drugs, 2021, 35, 545-565.	2.7	25
487	Withdrawal failure in patients with chronic migraine and medication overuse headache. Acta Neurologica Scandinavica, 2021, 144, 408-417.	1.0	6
488	Brain function state in different phases and its relationship with clinical symptoms of migraine: an fMRI study based on regional homogeneity (ReHo). Annals of Translational Medicine, 2021, 9, 928-928.	0.7	10
489	The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache, 2021, 61, 1021-1039.	1.8	286
490	Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomedicine and Pharmacotherapy, 2021, 139, 111557.	2.5	51
491	Standardized Headache Therapy in the Pediatric Emergency Department Using Improvement Methodology. Pediatric Quality & Safety, 2021, 6, e443.	0.4	1
492	Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. Myâ€IFE European Delphi survey. European Journal of Pain, 2021, 25, 2177-2189.	1.4	1
493	White matter changes in the trigeminal spinal tract in chronic migraineurs. Pain, 2021, Publish Ahead of Print, .	2.0	4
494	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. Journal of Pain Research, 2021, Volume 14, 2529-2542.	0.8	6
495	Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data. Headache, 2021, 61, 1245-1254.	1.8	12
496	Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives. Frontiers in Pain Research, 2021, 2, 705276.	0.9	31
497	A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraineâ€associated symptoms: A post hoc analysis. Headache, 2021, 61, 1227-1233.	1.8	1

#	Article	IF	CITATIONS
498	The structural and functional importance of the thalamus in migraine processes with and without aura. A literature review. Translational Research in Anatomy, 2021, 24, 100130.	0.3	5
499	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia, 2022, 42, 197-208.	1.8	14
500	Nerivio < sup > \hat{A}^{\otimes} < /sup > remote electrical neuromodulation for acute treatment of chronic migraine. Pain Management, 2022, 12, 267-281.	0.7	7
501	Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States. Journal of Managed Care & Decialty Pharmacy, 2021, 27, 1157-1170.	0.5	4
503	Breaking the cycle of medication overuse headache. , 2021, 70, 20-28.		1
504	Medication Overuse and Headache Burden. Neurology: Clinical Practice, 2021, 11, 216-226.	0.8	25
505	Comparison of 3 Treatment Strategies for Medication Overuse Headache. JAMA Neurology, 2020, 77, 1069.	4.5	71
508	Medication-Overuse Headache (MOH). Headache, 2016, , 207-222.	0.2	1
509	Epidemiology of Headache. Headache, 2016, , 7-18.	0.2	3
510	Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurological Sciences, 2017, 38, 201-206.	0.9	50
511	Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Review of Neurotherapeutics, 2020, 20, 627-641.	1.4	45
512	Contributions of Epidemiology to Our Understanding of Migraine. Headache, 2013, 53, 230-246.	1.8	152
513	Management of medication overuse headache. BMJ: British Medical Journal, 2010, 340, c1305-c1305.	2.4	5
514	Acupuncture as prophylaxis for chronic migraine: a protocol for a single-blinded, double-dummy randomised controlled trial. BMJ Open, 2018, 8, e020653.	0.8	17
515	Oral Chinese Herbal Medicine as Prophylactic Treatment for Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-20.	0.5	9
516	The role of left prefrontal transcranial magnetic stimulation in episodic migraine prophylaxis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	8
517	Calcitonin gene-related peptide: A molecular link between obesity and migraine?. Drug News and Perspectives, 2010, 23, 112.	1.9	48
518	The paradoxical effects of analgesics and the development of chronic migraine. Arquivos De Neuro-Psiquiatria, 2011, 69, 544-551.	0.3	7

#	Article	IF	CITATIONS
519	An Overview of the Treatment Options for Acute Migraine. European Neurological Review, 2011, 6, 265.	0.5	2
520	Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 170-188.	1.1	7
522	Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. Journal of Clinical Medicine, 2021, 10, 67.	1.0	7
523	Breaking the cycle of medication overuse headache. Cleveland Clinic Journal of Medicine, 2010, 77, 236-242.	0.6	44
524	The Acute Treatment of Migraine Attack in Adults and American Headache Society Evidence Assessment of Migraine Pharmacotherapies. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2016, 22, 3-7.	0.1	3
525	Association between primary headaches and temporomandibular disorders. Journal of the American Dental Association, 2022, 153, 120-131.e6.	0.7	16
526	Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study. Yearbook of Neurology and Neurosurgery, 2009, 2009, 42-43.	0.0	0
527	Headache, facial pain, and disorders of facial sensation. , 2010, , 661-684.		1
529	Prevention of migraine. BMJ: British Medical Journal, 2010, 341, c5229-c5229.	2.4	1
531	Medical Interventions for Migraine That Has Become Difficult to Treat. , 2011, , 423-434.		0
532	Treatment of Medication Overuse Headache. , 2011, , 153-166.		1
533	EpidemiologÃa y clasificación. , 2011, , 1-14.		0
534	Medication Overuse and Headache., 2011,, 637-650.		2
535	Migra $ ilde{A}$ $\pm a$ cr $ ilde{A}$ 3 nica. , 2011, , 143-165.		0
538	Loosening the grip of migraine attacks. Pharmacy Today, 2012, 18, 61-72.	0.0	0
541	Therapy of Migraine. , 2014, , 29-46.		0
542	Diagnosis of Addiction, Substance Use, and Headache., 2014,, 63-76.		0
543	Migraine, Medication Overuse Headache and. , 2014, , 53-57.		0

#	Article	IF	CITATIONS
544	Acute Treatment of Episodic Migraine. , 2014, , 145-159.		0
545	Medical Treatment of Refractory Daily Headaches, Including Interdisciplinary Management. , 2014, , 213-225.		0
547	Pharmacotherapy and Other Medical Treatments. , 2016, , 43-67.		0
549	Sorting Through Headache Patterns. , 2017, , 1-20.		O
550	Differential Diagnosis and Workup of the Headache Patient: Should I Order a Scan?., 2017, , 17-35.		0
551	The Effect of Bilateral Block of Greater Occipital Nerve on Chronic Migraine. Journal of the Royal Medical Services, 2017, 24, 57-61.	0.0	0
552	Medication Overuse Headache. , 2018, , 1113-1113.		0
553	Migraine and depression: a comparative assessment of the efficacy and safety of antidepressants in patients with migraine. Journal of Neurology & Stroke, 2018, 8, .	0.0	0
554	Opioids and Migraine: Opioid Awareness and Frequency of Use among Turkish Migraineurs. Safety and Risk of Pharmacotherapy, 2019, 7, 139-145.	0.1	0
555	Drug-induced headache in young people of reproductive age with tobacco addiction. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2020, 26, 28-32.	0.1	0
556	Achievements of Recent Decades in the Diagnosis and Study of Migraine Pathogenesis. Human Physiology, 2020, 46, 870-879.	0.1	1
557	Pathophysiology and Diagnosis of Nerve Compression Headache. , 2020, , 1-13.		O
558	Clinical and biobehavioral perspectives: Is medication overuse headache a behavior of dependence?. Progress in Brain Research, 2020, 255, 371-402.	0.9	4
561	Cluster-Then-Classify Methodology for the Identification of Pain Episodes in Chronic Diseases. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 2339-2350.	3.9	5
562	Caffeine as analgesic adjuvant. , 2022, , 63-72.		2
563	Medication overuse headache and awareness. Arquivos De Neuro-Psiquiatria, 2021, 79, 1095-1100.	0.3	2
564	Migraine Preventive Therapy; Focus on β-blockers; Literature Review. Pharmacophore, 2021, 12, 104-107.	0.2	2
565	Calcitonin-Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention; Literature Review. World Journal of Environmental Biosciences, 2021, 10, 48-51.	0.1	0

#	Article	IF	CITATIONS
566	Disrupted Dynamic Functional Connectivity of the Visual Network in Episodic Patients with Migraine without Aura. Neural Plasticity, 2022, 2022, 1-10.	1.0	7
567	Medication-Overuse Headache: Results from a Pain Medicine Clinic Cohort., 0,,.		1
568	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache, 2022, 62, 122-140.	1.8	43
569	Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. Cephalalgia Reports, 2022, 5, 251581632210755.	0.2	4
570	Applicability of DSM-V substance use disorder (SUD) criteria in medication overuse headache (MOH). Headache Medicine, 0, , 240-246.	0.1	0
571	The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review. Korean Journal of Pain, 2022, 35, 4-13.	0.8	3
572	Preventive and Therapeutic Aspects of Migraine for Patient Care: An Insight. Current Molecular Pharmacology, 2023, 16, 147-160.	0.7	1
573	Broadening vestibular migraine diagnostic criteria: A prospective cohort study on vestibular migraine subtypes. Journal of Vestibular Research: Equilibrium and Orientation, 2022, 32, 453-463.	0.8	6
574	Patient-Centered Treatment of Chronic Migraine With Medication Overuse. Neurology, 2022, 98, .	1.5	28
575	Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments. Current Pain and Headache Reports, 2022, 26, 347-355.	1.3	14
576	New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach. International Journal of Molecular Sciences, 2022, 23, 3018.	1.8	4
577	Lifestyle Modifications for Migraine Management. Frontiers in Neurology, 2022, 13, 719467.	1.1	18
578	Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007–2018 National Hospital Ambulatory Medical Care Survey Data. Journal of Clinical Medicine, 2022, 11, 1401.	1.0	6
579	Head/neck pain characteristics after spontaneous cervical artery dissection in the acute phase and on a long-run. Cephalalgia, 2022, 42, 872-878.	1.8	4
580	Peripheral Nerve Blocks for Headache: A Precise Approach to Pain Management in the Emergency Department. Annals of Emergency Medicine, 2022, 79, 262-264.	0.3	1
581	Association between patent foramen ovale and migraine without aura: a community-based cross-sectional study in China. BMJ Open, 2022, 12, e056937.	0.8	7
582	Migraine patients visiting Chinese medicine hospital: Protocol for a prospective, registry-based, real-world observational cohort study. PLoS ONE, 2022, 17, e0265137.	1.1	2
583	OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients. Brain, 2022, 145, 2436-2449.	3.7	12

#	Article	lF	CITATIONS
584	Fiorinal and Fioricet., 0,, 262-266.		0
586	CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies. Current Pain and Headache Reports, 2022, 26, 543-554.	1.3	6
587	Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. Journal of Headache and Pain, 2022, 23, 56.	2.5	18
589	Efficacy of ultrasound-guided greater occipital nerve pulsed radiofrequency therapy in chronic refractory migraine. Acta Neurologica Belgica, 2023, 123, 191-198.	0.5	6
590	Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. European Journal of Medical Research, 2022, 27, .	0.9	15
591	Neurobiology of migraine progression. Neurobiology of Pain (Cambridge, Mass), 2022, 12, 100094.	1.0	14
592	Histone Deacetylase Inhibitors Counteract CGRP Signaling and Pronociceptive Sensitization in a Rat Model of Medication Overuse Headache. Journal of Pain, 2022, 23, 1874-1884.	0.7	4
593	Efficacy and Safety of Oral Chinese Herbal Medicine for Migraine: A Systematic Review and Meta-Analyses Using Robust Variance Estimation Model. Frontiers in Neurology, 0, 13, .	1.1	3
594	Clinical characteristics of medicationâ€overuse headache according to the class of acute medication: A crossâ€sectional multicenter study. Headache, 2022, 62, 890-902.	1.8	4
595	Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype. Headache, 2022, 62, 828-838.	1.8	5
596	Acute Headache Management for Patients with Subarachnoid Hemorrhage: An International Survey of Health Care Providers. Neurocritical Care, 2023, 38, 395-406.	1.2	9
597	Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). Journal of Medical Economics, 2022, 25, 1030-1038.	1.0	1
598	Association of a Cyclical Migraine Phenotype With Disease Progression. Neurology, 2022, 99, .	1.5	3
601	Mechanisms. , 2022, , 211-452.		0
602	Pathophysiology and Therapy of Associated Features of Migraine. Cells, 2022, 11, 2767.	1.8	11
603	The Epidemiology of Primary Headache Disorders. Seminars in Neurology, 2022, 42, 449-458.	0.5	3
604	Medication Prescribing Status in Pediatric Patients with Migraine. Korean Journal of Clinical Pharmacy, 2022, 32, 178-184.	0.0	0
605	Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine. Current Medical Research and Opinion, 2023, 39, 105-112.	0.9	2

#	Article	IF	CITATIONS
606	Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Current Pain and Headache Reports, 2022, 26, 843-854.	1.3	4
607	The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports, 2022, 5, 251581632211345.	0.2	0
608	Refractory Headaches. Seminars in Neurology, 2022, 42, 512-522.	0.5	1
609	Migraine treatment in patients with poor compliance. Neurologie Pro Praxi, 2022, 23, 324-329.	0.0	0
610	Chronic Migraine. Neurologic Clinics, 2023, 41, 141-159.	0.8	5
611	Rimegepant for the treatment of migraine. Health Psychology Research, 2022, 10, .	0.6	4
612	Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults. Health Psychology Research, 2022, 10 , .	0.6	0
613	Adverse Childhood Experiences and Medication Overuse Headache: Burden and Treatment Impact. Canadian Journal of Neurological Sciences, 2023, 50, 918-921.	0.3	1
614	Prevention of Migraine. Seminars in Neurology, 2022, 42, 558-570.	0.5	0
616	Altered functional connectivity of the right caudate nucleus in chronic migraine: a resting-state fMRI study. Journal of Headache and Pain, 2022, 23, .	2.5	6
617	Prophylactic and Acute Pharmacology for Pediatric Headache. , 2022, , 157-174.		0
618	Changes in gammaâ€aminobutyric acid and glutamate/glutamine levels in the right thalamus of patients with episodic and chronic migraine: A proton magnetic resonance spectroscopy study. Headache, 2023, 63, 104-113.	1.8	3
619	A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role. Toxins, 2023, 15, 86.	1.5	2
620	Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine. Journal of Occupational and Environmental Medicine, 2023, 65, e261-e268.	0.9	0
621	Lifetime history of an anxiety or depression disorder and adherence to medications used for the acute treatment of migraine. Headache, 0 , , .	1.8	0
622	Efficacy and safety of two different botulinum toxin type A dilutions in chronic migraineurs. Toxicon, 2023, 227, 107096.	0.8	1
623	Sex differences in clinical characteristics of migraine and its burden: a populationâ€based study. European Journal of Neurology, 2023, 30, 1774-1784.	1.7	7
624	Transitioning from Pediatric to Adulthood with Regard to Headaches and Their Subsequent Care., 2022,, 177-190.		0

#	ARTICLE	IF	CITATIONS
625	Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine. Clinical Neurology and Neurosurgery, 2023, 226, 107609.	0.6	1
626	Redefining Expectations for Migraine Prevention. Touch Reviews in Neurology, 2021, 17, 2.	0.1	0
627	Medication overuse headache. Nature Reviews Disease Primers, 2023, 9, .	18.1	23
628	Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia, 2023, 43, 033310242211416.	1.8	7
630	Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study. Frontiers in Neurology, 0, 14, .	1.1	2
631	Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review. Life, 2023, 13, 665.	1.1	1
633	Sex differences in migraine attack characteristics: A longitudinal Eâ€diary study. Headache, 2023, 63, 333-341.	1.8	5
634	Clinical Instruments for Treatment Monitoring and Optimization in Headache and Migraine. Headache, 2023, , 139-149.	0.2	0
635	Headache impact and socioeconomic status: findings from a study of the German Migraine and Headache Society (DMKG). Journal of Headache and Pain, 2023, 24, .	2.5	5
636	Changes in Migraine in the COVID-19 Pandemic Era. Headache, 2023, , 179-190.	0.2	0
637	Early maladaptive schemas in episodic and chronic migraine in adolescents. Frontiers in Neurology, 0, 14, .	1.1	0
638	The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review. Pain and Therapy, 2023, 12, 655-669.	1.5	0
652	Risk factors for migraine disease progression: a narrative review for a patient-centered approach. Journal of Neurology, 2023, 270, 5692-5710.	1.8	5
653	Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review. Neurology and Therapy, 2023, 12, 1533-1551.	1.4	1
665	What has neurophysiology revealed about migraine and chronic migraine?. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 117-133.	1.0	0
671	Management of medication overuse headache. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 277-299.	1.0	0
672	Evidence-based symptomatic treatment of migraine. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 203-218.	1.0	0
675	Treatment in the emergency department. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 245-256.	1.0	0

Article IF Citations